34,891 results on '"PHEOCHROMOCYTOMA"'
Search Results
2. First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study
3. Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
4. Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
5. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
6. Diagnosis of Pheochromocytoma
7. Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
8. Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
9. Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)
10. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
11. Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
12. Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) (MICROBAT)
13. Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease (VHLimage)
14. Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
15. Adrenal Tumors - Pathogenesis and Therapy
16. Using the EHR to Advance Genomic Medicine Across a Diverse Health System
17. Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
18. The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma
19. Postmortem Evaluation of Adrenal and Other Endocrine Tumors in Patients With Sudden Death (SuddenDeath)
20. Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT)
21. 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
22. Side-specific Factors for Conversion in Adrenalectomy for Pheochromocytoma.
23. Intraoperative Hemodynamic Instability in Adrenalectomy for Pheochromocytoma.
24. Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
25. Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
26. Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data
27. 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
28. Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
29. 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System
30. MIBG for Refractory Neuroblastoma and Pheochromocytoma
31. DOTATOC PET/CT for Imaging NET Patients
32. HTL0039732 in Participants With Advanced Solid Tumours
33. Complex Presentation of Pheochromocytoma: Hypertensive Encephalopathy and Takotsubo-Like Cardiomyopathy in a Young Female.
34. Unveiling Pheochromocytoma: A Puzzling Prelude of Nausea, Vomiting, and Abdominal Pain.
35. Metastatic disease and major adverse cardiovascular events preceding diagnosis are the main determinants of disease-specific survival of pheochromocytoma/ paraganglioma: long-term follow-up of 303 patients.
36. Prevention and management of hypertensive crises in children with pheochromocytoma and paraganglioma.
37. Hot Trends in Pheochromocytoma and Paraganglioma: Are We Getting Closer to Personalized Dynamic Prognostication?
38. Clues for Early Diagnosis of MEN2B Syndrome Before Medullary Thyroid Carcinoma.
39. Genetic variants and down-regulation of CACNA1H in pheochromocytoma.
40. Approach to the Patient: Concept and Application of Targeted Radiotherapy in the Paraganglioma Patient.
41. Outcomes of SDHB Pathogenic Variant Carriers.
42. Dielectric characterisation of human adrenal glands and adrenal tumours for the development of microwave ablation technologies for hypertension treatment.
43. Extensive patient-to-patient single nucleus transcriptome heterogeneity in pheochromocytomas and paragangliomas.
44. Diffuse pulmonary hemorrhage as a rare presentation of pheochromocytoma: a case report with review of the literature.
45. Side-specific factors for intraoperative hemodynamic instability in laparoscopic adrenalectomy for pheochromocytoma: a comparative study.
46. EPAS1-related pheochromocytoma/ paraganglioma.
47. Pheochromocytoma/Paraganglioma Syndrome Type 1 Presenting with Atypical Symptoms and a Novel Pathogenic Variant in the SDHD Gene: A Case Report.
48. Approach to the Patient With Bilateral Adrenal Masses.
49. Prenylated dihydroflavones from the root barks of Morus alba.
50. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.